Dendreon, Geron jobs cut after Valeant, Janssen deals
This article was originally published in Scrip
Valeant Pharmaceuticals pulled Dendreon out of bankruptcy by acquiring the troubled prostate cancer immunotherapy company, and Johnson & Johnson's Janssen Biotech subsidiary pumped much-needed cash into Geron with a drug development partnership, but because of those deals 95 people at Dendreon and Geron are losing their jobs.
You may also be interested in...
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.